Schonfeld Strategic Advisors’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-40,000	Closed	-$10K	–	3235
2022 Q1	$10K	Hold	40,000	–	–	﹤0.01%	2424
2021 Q4	$26K	Buy	40,000 +15,000	+60%	+$10.4K	﹤0.01%	1978
2021 Q3	$16K	Buy	+25,000	New	+$18.6K	﹤0.01%	2059

Schonfeld Strategic Advisors's BIOTW Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 30,000 shares — an estimated $1.92K sold.

Schonfeld Strategic Advisors first reported a position in BIOTW in Q2 2022 and held it in 3 quarters. The position peaked at $3K in Q2 2022. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Schonfeld Strategic Advisors reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 30,000 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $1.92K.
Schonfeld Strategic Advisors first reported a position in Biotech Acquisition Company Warrant in Q2 2022 and held it in 3 quarters.
Schonfeld Strategic Advisors's Biotech Acquisition Company Warrant position peaked at $3K in Q2 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.